SCHEMBL1033005

SCHEMBL1033005

COc1ccc(Cl)cc1-c1ccnc(S(C)(=O)=O)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
JAK2 O60674 1/20 0.44
AGPAT2 O15120 6/20 0.43
SCN9A Q15858 2/20 0.43
HPGD P15428 4/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MITF O75030 1/20 0.43
STAT3 P40763 1/20 0.43
CDK9 P50750 2/20 0.42
AURKA O14965 1/20 0.42
MAP4K4 O95819 1/20 0.42
ABL1 P00519 1/20 0.42
LCK P06239 1/20 0.42
MET P08581 1/20 0.42
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033197 0.80 ALDH1A1 (0.55) KDM4EALDH1A1JAK2AGPAT2HPGD
SCHEMBL1033206 0.76 LMNA (0.53) KDM4EALDH1A1JAK2AGPAT2HPGD
SCHEMBL4071288 0.74 KMO (0.51) JAK2LMNAHTTMAP4K4CLK4
SCHEMBL3250098 0.73 MAPT (0.39) KDM4EJAK2SCN9AHPGDLMNA
SCHEMBL3399379 0.72 ALDH1A1 (0.51) KDM4EALDH1A1AGPAT2HPGDNPSR1
SCHEMBL1264511 0.72 BPTF (0.42) KDM4ELMNACDK9AURKAMAP4K4
SCHEMBL1032946 0.71 PIK3CA (0.60) JAK2AGPAT2CDK9AURKAMAP4K4
SCHEMBL3914041 0.70 PTGS2 (0.38) KDM4ESCN9AHPGDLMNAHTT
SCHEMBL3909205 0.70 CYP3A4 (0.39) KDM4EALDH1A1SCN9AHPGDNPSR1
SCHEMBL3911204 0.69 BRAF (0.42) MAP4K4MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed